Cellebrite DI (NASDAQ:CLBT) Posts Earnings Results, Hits Estimates

Cellebrite DI (NASDAQ:CLBT) released its quarterly earnings results on Wednesday. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14, Briefing.com reports. The company had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The firm’s revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share.

Here are the key takeaways from Cellebrite DI’s conference call:

• Strong 2025 financials — ARR grew 21% to $481M (17% ex‑Corellium), full‑year revenue +19%, Adjusted EBITDA expanded and free cash flow totaled $160M (34% margin).
• SaaS and cloud momentum — SaaS/cloud ARR grew >50% and now represents 22% of total ARR; Guardian sustained 100%+ YoY growth for its sixth straight quarter, boosting recurring, higher‑margin revenue.
• M&A to broaden TAM — Closed Corellium (Dec 1) and agreed to buy SCG Canada (drone forensics) to add ARM virtualization and drone capabilities; management expects long‑term accretion but Corellium adds near‑term costs and regulatory/clearance work remains.
• 2026 guidance and tighter outlook — Management set narrower targets calling for 18–19% ARR growth (to $567–573M), revenue +19–20% and Adjusted EBITDA margin ~26–27%, while targeting FCF margins >30%.
• Federal market catalysts — Company expects the U.S. federal unit to reaccelerate on pent‑up demand, increased funding and an anticipated FedRAMP Level 4 ATO that will enable Guardian/cloud adoption in federal accounts.

Cellebrite DI Stock Down 5.6%

NASDAQ:CLBT traded down $0.80 during midday trading on Thursday, hitting $13.46. The stock had a trading volume of 1,540,675 shares, compared to its average volume of 1,736,041. The stock has a 50-day moving average of $17.21 and a 200 day moving average of $17.00. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of 43.40, a PEG ratio of 2.08 and a beta of 1.28. Cellebrite DI has a one year low of $13.10 and a one year high of $25.03.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors have recently added to or reduced their stakes in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after acquiring an additional 24,881 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after buying an additional 43,898 shares in the last quarter. Invesco Ltd. lifted its position in Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after buying an additional 209,473 shares in the last quarter. First Trust Advisors LP acquired a new stake in Cellebrite DI during the second quarter worth about $341,000. Finally, Marshall Wace LLP purchased a new position in Cellebrite DI in the second quarter worth approximately $4,472,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Reported strong Q4 results — revenue $128.8M (+28.8% YoY), total ARR up 21% to $480.8M, healthy adjusted EBITDA margin (~29.8%), and positive net income metrics, reinforcing fundamentals. PR Newswire: Q4 & FY2025 Results
• Positive Sentiment: Raised FY‑2026 revenue guidance of $565M‑$571M (above consensus ~$556M), and Q1 revenue guidance roughly in line with Street expectations — the top‑line outlook supports continued growth expectations. Press Release / Slide Deck
• Positive Sentiment: Needham left a Buy rating and ($18) target — even after the cut this implies material upside from current levels, which may limit downside and attract value/higher‑conviction buyers. Benzinga: Needham Price Target Note
• Neutral Sentiment: EPS matched expectations at $0.14 (no earnings surprise), and revenue slightly above consensus — confirms execution but lacks an upside shock. Zacks: Q4 Results
• Neutral Sentiment: Earnings call transcripts and highlights are available (Seeking Alpha, Yahoo) for investors wanting management detail on bookings, ARR cadence and margin drivers. Seeking Alpha: Call Transcript Yahoo Finance: Call Highlights
• Negative Sentiment: Needham trimmed its price target from $24 to $18 — the cut signals reduced near‑term upside expectations and may lower analyst support despite the maintained Buy. Benzinga: Needham Price Target Note
• Negative Sentiment: Technicals and positioning are weak: CLBT is trading below its 50‑ and 200‑day moving averages and near its 12‑month low, which can amplify downside pressure as momentum traders stay on the sidelines. (See market performance data.)

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Bank of America boosted their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Needham & Company LLC cut their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and an average target price of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.